Anti-infection
-
C8697 IbrexafungerpSummary: The first novel triterpenoid oral antifungal drug, with the core target being 1,3-β-D - glucan synthase in the fungal cell wall. -
C8707 Quinine bisulfateSummary: An antimalarial drug whose primary target is the hemoglobin metabolism pathway during the intraerythrocytic stage of Plasmodium.